Metylfenidat Actavis

Methylphenidate, the active ingredient in Metylfenidat Actavis, is a central nervous system stimulant presented as an oral formulation for oral use. It is prescribed to manage attention deficit hyperactivity disorder and narcolepsy in children, adolescents, and adults.

GNH USA supplies Metylfenidat Actavis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑compliant documentation for global distribution.

Methylphenidate is used in central nervous system stimulant therapy for neurodevelopmental and sleep‑wake disorders.

ADHD: improves attention, reduces hyperactivity and impulsivity in patients with attention deficit hyperactivity disorder. Narcolepsy: decreases excessive daytime sleepiness and cataplexy episodes in individuals with narcolepsy.

Methylphenidate may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Insomnia: difficulty falling or staying asleep. - Decreased appetite: reduced hunger leading to weight loss. - Headache: mild to moderate cranial pain. - Stomach upset: nausea or abdominal discomfort.

Serious or Rare Side Effects: - Cardiovascular events: chest pain, hypertension, or arrhythmias. - Psychosis: hallucinations or delusional thoughts. - Severe allergic reaction: rash, swelling, or anaphylaxis.

When prescribing methylphenidate, clinicians should consider several safety precautions to minimize risks.

- Cardiovascular assessment: evaluate history of heart disease, hypertension, or arrhythmias before initiating therapy. - Growth monitoring: regularly track height and weight in children and adolescents during treatment. - Psychiatric evaluation: assess for pre‑existing psychosis, bipolar disorder, or severe anxiety before use. - Drug interaction caution: avoid concurrent use with monoamine oxidase inhibitors or other potent sympathomimetics. - Abuse potential: recognize the risk of dependence and misuse, especially in individuals with a substance‑use history. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Methylphenidate can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - MAO inhibitors: concurrent use may cause hypertensive crisis or serotonin syndrome. - Tricyclic antidepressants: increased risk of cardiovascular side effects and heightened stimulant effect. - Antipsychotics (e.g., haloperidol): may reduce methylphenidate’s therapeutic benefit.

Moderate Interactions (Monitor Closely): - SSRIs and SNRIs: may enhance serotonergic activity, requiring observation for mood changes. - Antihypertensive agents: methylphenidate can diminish blood‑pressure‑lowering effects. - Oral contraceptives: possible reduction in contraceptive efficacy due to enzyme induction. - Carbamazepine: may lower methylphenidate plasma levels, reducing effectiveness.